Restrictions reimposed or extended around the world; Remdesivir for 127 countries; Venezuela and Brazil, epicenters of risk. The ASG global COVID-19 update

A detailed analysis of the global progression of the pandemic, and of government’s responses, prepared by the global strategic advisory and commercial diplomacy firm, Albright Stonebridge Group. Key Takeaways This week we continue to see governments around the world reimpose or extend restrictions in the face of resurging case numbers, often at the provincial or local levels. Gilead struck a licensing agreement with five generic drug makers, including Mylan, Cipla, Ferozsons Laboratories, Hetero Labs, and Jubilant Lifesciences, to make the antiretroviral Remdesivir for 127 countries “royalty free” until the COVID-19 outbreak is no longer a global health crisis. Venezuela, Bangladesh, Nigeria, and Yemen, refugee camps, warzones, and other areas with limited testing and health infrastructure threaten the possibility of widespread undetected […]

Related

“Latin America, the vision of its leaders” A book by Andrés Rugeles and 100 regional leaders

The Colombian Andrés Rugeles has achieved an almost impossible...

Global Tourism Industry on Track for Full Recovery by 2024

The global tourism industry is set to reach, and possibly surpass, pre-pandemic levels by the end of 2024, according to the World Economic Forum (WEF). Five years post-COVID-19, the sector is experiencing a robust resurgence driven by a surge in international travel, improved air connectivity, and strong rebounds in key regions. However, global dynamics must be managed carefully to ensure stable and continuous growth. In 2023, international tourism reached 88% of its 2019 levels, a significant recovery favored by the reopening of Asian markets, as highlighted by the United Nations World Tourism Organization (UNWTO). The Middle East led the way, surpassing pre-pandemic levels by around 20%, with Europe, the Americas, and Africa following close behind at approximately 90% of their […]